Managing Multiple Myeloma: How Emerging Therapies Can Help The Leukemia & Lymphoma Society of Canada invites you to learn more about multiple myeloma. Dr. Ismail Sharif will provide an overview of the current and emerging treatment options, and share information on how to manage symptoms and treatment-related side effects.

Multiple Myeloma Abstracts Dealing with Health Disparities Presented at ASH 2021 IMF Chief Medical Officer Dr. Joseph Mikhael Addresses Disparities in Myeloma Care From ASH 2021 _______________ Improving Lives | Finding the Cure In the United States, an estimated 32,270 new multiple myeloma cases will be diagnosed in 2021. 159,985 new myeloma cases are diagnosed […]

Pathology — dr.Nafe'a — Plasma cell tumors (1) — Multiple Myeloma اللهم صل وسلم على سيدنا وحبيبنا وشفيعنا محمد وعلى آله وصحبه أجمعين .. ومن يتق الله يجعل له مخرجاَ .. ويرزقه من حيث لا يحتسب .. احفظ الله يحفظك .. احفظ الله تجده تجاهك .. واجعلوا لنا نصيباَ من دعائكم .. 

Natural Killer Cells as Add-on Therapy for Multiple Myeloma is Showing Promise in the Lab Nina Shah, MD, Hematologist from the University of California, San Francisco, discusses preclinical data demonstrating that a subset of human natural killer (NK) cells that lack expression of FcεRIγ (g-NK cells) enhance the efficacy of monoclonal antibody treatment in multiple […]

Iberdomide + dexamethasone in R/R multiple myeloma Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, University College London Hospitals, London, UK, presents the results of a study evaluating iberdomide, a cereblon E3 ligase modulator (CELMoD) agent, in combination with dexamethasone in patients with triple-class refractory multiple myeloma or in patients who have been exposed to an […]

Our Ongoing Commitment to Multiple Myeloma Patients Globally, about 176K people were diagnosed with #MultipleMyeloma (MM) in 2021. Despite current treatment options, high relapse rates require innovative approaches. We’re working to evolve research around #BCMA, a promising target in MM. For more: https://www.mmwayforward.com/ #EBMT22

Discussing in "Multiple Myeloma"

The changing landscape of induction therapy for newly diagnosed multiple myeloma Elias Mai, MD, University Hospital Heidelberg, Heidelberg, Germany, outlines new agents added to induction strategies in patients with newly diagnosed transplant-eligible multiple myeloma. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Approved and emerging CAR-Ts in multiple myeloma Hermann Einsele, MD, FRCP, University of Würzburg, Würzburg, Germany, comments on the efficacy and safety of idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), two chimeric antigen receptor T-cell (CAR-T) therapies for multiple myeloma. Ide-cel has been approved by the FDA and EMA for patients with multiple myeloma who […]

Improving the management of multiple myeloma Elena Zamagni, MD, PhD, University of Bologna, Bologna, Italy, briefly explains the importance of accurate evaluation of patients with multiple myeloma. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.